Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

DDX41-related myeloid neoplasms: Insights and treatment landscape in 250 patients managed at a large tertiary centre

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPramila KrishnamurthyVPVictoria PotterVMVarun Mehra

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals treatment strategies and survival analysis for myeloid neoplasms, emphasizing venetoclax efficacy.

Key Points

  • Clinical data show that treatment strategies displayed limited efficacy but highlighted high response rates for venetoclax.
  • Survival analysis found that myeloid neoplasms associated with DDX41 mutations had variable prognosis based on mutation type.
  • Molecular data indicated significant differences in treatment responses based on the presence of somatic mutations, impacting overall outcomes.
  • Overall response rate reached 74%, driven largely by strategies including venetoclax and intensive chemotherapy regimens.

Cite This Study

Krishnamurthy et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e04ehttps://doi.org/10.1182/blood-2025-5262
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decoding DDX41: Clinical impact of germline and somatic mutations in 77 high-risk myeloid neoplasm patients2025 · 1 citations
  2. 2Improved outcomes following allogeneic hematopoietic stem cell transplantation in patients with DDX41-mutated myeloid neoplasms: A prospective analysis of survival, GVHD, and transplant-related mortality2025
  3. 3Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025
  4. 4Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits2025
  5. 5Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies2025 · 7 citations